Navigation Links
Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
Date:7/7/2010

any expects additional U.S. and European patent issuances related to the Zamore portfolio in the coming months.

"This latest in a series of related patent issuances continues to highlight the significant value of the groundbreaking Zamore patent families.  For the second time in the past month, we have strengthened our rapidly expanding RNAi IP position with a key patent issuance in the area of structural modification technology," stated Philip Haworth, Ph.D., chief executive officer of Silence Therapeutics.  "Whereas our last patent provided key guidance in enhancing the desired silencing activity of RNAi agents, this latest patent covers the equally valuable ability to minimize the undesired off-target silence activity of RNAi agents."

Silence Therapeutics is executing a proactive strategy to continue to build and strengthen a diverse and competitive intellectual property portfolio that provides the company and its partners with a strong proprietary position in the RNAi therapeutics space.  The company believes that it will continue to make significant progress in these efforts throughout 2010 as it expects a number of additional valuable RNAi patents to be issued in both the United States and Europe during the year.  This consistent and meaningful IP portfolio growth reinforces Silence's belief that the company can sustain its position as a preferred partner in RNAi therapeutics. At present, Silence's global patent portfolio contains issued patents and pending applications covering strategic areas of RNAi therapeutic development including multiple proprietary siRNA delivery technologies, potent siRNA sequences specific for high-value disease targets and key RNAi sequence and chemical modifications.

About Silence Therapeutics plc (

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
2. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
3. Silence Therapeutics Announces Successful Opposition of Glover Patent
4. Organizational Changes at Silence Therapeutics
5. Silence Obtains Important Patent Protection for Lead Internal Development Compound, Atu027
6. Silence Therapeutics Patent Update
7. Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent
8. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
9. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
10. Silence Therapeutics Appoints New Vice President of Research
11. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... LONDON , Nov. 21, 2014  The element ... in emerging diseases, i.e., they strike without warning. Until ... advance warning of a viral outbreak, resulting in suboptimal ... to Ebola currently. Photo - ... surprise has now been removed because virus gene structural ...
(Date:11/21/2014)... , November 21, 2014 , ... comercial   Mariano Rodríguez es elegid vicepresidente ... KLOX está en marcha para comenzar de forma ... de heridas de reciente aprobación en Europa   , ... se complace al anunciar los siguientes nombramientos: ...
(Date:11/21/2014)... BELLINGHAM, Washington, USA (PRWEB) November 19, 2014 ... used in our lives was shared with more than ... undergraduate and postgraduate students from the University of Otago ... Outreach Grant . The Otago students, members of the ... Southland New Zealand in early September, giving children from ...
(Date:11/21/2014)... 20, 2014 Author Matthew J. Pallamary’s ... the Other Side” published as a tribute to ... the “Fiction: Short Story” category of the 2014 ... and CEO of USA Book News, said this year’s ... publishers, including Simon & Schuster, Penguin, John Wiley & ...
Breaking Biology Technology:Viruses' Advantage of Surprise is Lost 2KLOX Technologies anuncia sus nombramientos ejecutivos 2KLOX Technologies anuncia sus nombramientos ejecutivos 3KLOX Technologies anuncia sus nombramientos ejecutivos 4KLOX Technologies anuncia sus nombramientos ejecutivos 5Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4
... Chromatography and Mass Spectrometry Application Report , ... Equine serum Acepromazine , Gargi Choudhary, ... Wayne Skinner and Scott Stanley, University of California, ... Acepromazine is widely used as a sedative in ...
... Application Note , Kevin J. McHale, ... Thermo Electron Corporation, Somerset, NJ, USA , ... Acrylamide has been identified as a potential human carcinogen. ... but acrylamide was recently discovered to be present at significant levels in ...
... James Batchelor, and Ed Alderman , Applied ... Kelly M. Clark, Joseph A. Hensley and Robert P. Weisbein ... , Jennifer L. Halcome and George R. Halley ... CO , Introduction , ...
Cached Biology Technology:Determination of Acepromazine and its Major Metabolite in Equine Serum by LC-MS/MS using the Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer 2Determination of Acepromazine and its Major Metabolite in Equine Serum by LC-MS/MS using the Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer 3Determination of Acepromazine and its Major Metabolite in Equine Serum by LC-MS/MS using the Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer 4Quantitation of Acrylamide in Food Samples on the Finnigan TSQ Quantum Discovery by LC/APCI-MS/MS 2Quantitation of Acrylamide in Food Samples on the Finnigan TSQ Quantum Discovery by LC/APCI-MS/MS 3Quantitation of Acrylamide in Food Samples on the Finnigan TSQ Quantum Discovery by LC/APCI-MS/MS 4Quantitation of Acrylamide in Food Samples on the Finnigan TSQ Quantum Discovery by LC/APCI-MS/MS 5Quantitation of Acrylamide in Food Samples on the Finnigan TSQ Quantum Discovery by LC/APCI-MS/MS 6Automation of the Eppendorf Perfectprep BAC 96 DNA Kit on the Caliper Life Sciences Sciclone ALH 3000 2Automation of the Eppendorf Perfectprep BAC 96 DNA Kit on the Caliper Life Sciences Sciclone ALH 3000 3Automation of the Eppendorf Perfectprep BAC 96 DNA Kit on the Caliper Life Sciences Sciclone ALH 3000 4
(Date:11/5/2014)... Kelly Redmond has dedicated his career to understanding ... a general audience. , As deputy director and ... at Nevada,s Desert Research Institute, Redmond has more ... application and dissemination of climate data to the ... Meeting in San Francisco on December 15-19, 2014 ...
(Date:11/4/2014)... of Utah engineers developed the first room-temperature fuel cell ... without needing to ignite the fuel. These new fuel ... power and sensors. , A study of the new ... journal ACS Catalysis . , Fuel cells convert ... fuel and an oxygen-rich source such as air. If ...
(Date:11/4/2014)... Medicine announced today that it is a Grand ... Bill & Melinda Gates Foundation. Laura Goetzl, ... Sciences; and Vice Chair of Research and Academic ... pursue an innovative global health and development research ... Neurodevelopment.", Grand Challenges Explorations (GCE) funds individuals worldwide ...
Breaking Biology News(10 mins):Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2Jet-fueled electricity at room temperature 2Temple University School of Medicine receives Grand Challenges Explorations grant 2
... - At a glance, a painting by Jackson Pollock (1912󈞤) ... on a canvas. A quantitative analysis of Pollock,s streams, ... at Boston College, reveals, however, that the artist had to ... the way that he did. The finding, published in ...
... Mensenchymal stem cells (MSCs), multipotent cells identified in ... be therapeutically effective in the immunosuppression of T-cells, the ... and suppressing chronic airway inflammation in some asthma cases. ... applications, they are cultured in fetal bovine serum. , ...
... has been followed by a decline in fertility rates in ... first concerted rise in fertility rates in the developed world ... "In a new study, scientists from the Vienna Institute ... the International Institute for Applied Systems Analysis (IIASA) identify that ...
Cached Biology News:Jackson Pollock, artist and physicist? 2Jackson Pollock, artist and physicist? 3Serum-free cultures help transplanted MSCs improve efficacy 2Fertility rates affected by global economic crisis 2
Recorder, 6", 7 Day, 1 Pen, 0 to 100°C, 220V, 50/60 Hz, for 4520, Customer Installed...
... STAR3000 HISTAR detection systems provide linking ... used with species specific primary antibodies ... specimens. Visualisation is accomplished using an ... novel polymer labelling technology. Secondary antibodies ...
Taq DNA Polymerase (T. aquaticus), 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzyme...
... AmpliTaq DNA Polymerase is ... the PCR process, a testimony to its ... activity profile makes it ideal for PCR ... to guarantee reproducible results. ,, AmpliTaq ...
Biology Products: